Hope of new treatment for severe asthma patients
New research from Japan brings hope of a new treatment for asthma patients resistant to corticosteroids. In a study published today in the journal Nature Communications, researchers from the RIKEN Center for Integrative Medical Sciences and Keio University in Japan report that a type of lymphocytes called natural helper (NH) cells plays a critical role in corticosteroid resistance and demonstrate that the anti-psychotic drug Pimozide can be used to overcome resistance to steroids in severe asthma patients.
Asthma is a chronic disease characterized by a persistent inflammation of the airways. The condition can be controlled with a moderate dose of inhaled corticosteroids in most patients. However, 5-10% of patients with “severe asthma” respond poorly to a maximal dose of steroids. These patients experience uncontrolled and frequent asthma symptoms that have a profound impact on their quality of life and health care costs. Unveiling the mechanism leading to steroid resistance in these patients is therefore crucial for the development of a new, effective therapy.
T lymphocytes and NH cells in the asthmatic lung produce proteins named interleukin (IL)-5 and IL-13 that are responsible for severe airway inflammation. In asthma patients, inhaled steroids function by suppressing both T lymphocytes and NH cells.
However, in severe asthma patients, another protein called interleukin-33 (IL-33) produced in the airways strongly activates NH cells to produce IL-5 and IL-13, leading to severe airway inflammation.
In the current study, the researchers led by Drs Shigeo Koyasu from RIKEN and Koichiro Asano from Keio University, employed an experimental mouse model for airway inflammation to study the pathway leading to IL-33-mediated NH activation. Their research shows that NH resistance to steroids is induced by the protein thymic stromal lymphopoietin (TSLP), present in the airways of severe asthma patients.
The team tested reagents that block the intracellular signals triggered by TSLP in NH cells. They identified one drug, Pimozide, an approved anti-psychotic drug, that restored the effects of steroids on NH cells.
“Therefore, administration of Pimozide or related drugs would be an effective treatment in human severe asthmatic patients,” conclude the authors.
For more information please contact:
Global Relations Office
Tel: +81-(0)48-462-1225 / Fax: +81-(0)48-463-3687
Kabata et al. “Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation” Nature Communications, 2013
RIKEN is Japan’s flagship research institute devoted to basic and applied research. Over 2500 papers by RIKEN researchers are published every year in reputable scientific and technical journals, covering topics ranging across a broad spectrum of disciplines including physics, chemistry, biology, medical science and engineering. RIKEN’s advanced research environment and strong emphasis on interdisciplinary collaboration has earned itself an unparalleled reputation for scientific excellence in Japan and around the world.
About the Center for Integrative Medical Sciences
The Center for Integrative Medical Sciences, based in Yokohama, aims to develop revolutionary medical therapies based on collaborative projects between researchers from different areas of science. By achieving a deeper understanding of homeostasis, and how the breakdown of homeostasis leads to disease, scientists at IMS are working to develop personalized preventive medicine and personalized medicine that can allow us to lead healthier lives. The centers focuses include genomics, immunology, allergies, inflammation, endocrinology, and the new field of metabolomics.